ライフサイエンスコーパス: nevirapine

1 ther weak synergy (efavirenz) or antagonism (nevirapine).

2 e or emtricitabine) with either efavirenz or nevirapine.

3 6 months of age who had no prior exposure to nevirapine.

4 ong young children with no prior exposure to nevirapine.

5 reatment with zidovudine and lamivudine plus nevirapine.

6 exposure and clearance for efavirenz but not nevirapine.

7 6 months after they had received single-dose nevirapine.

8 than did women without previous exposure to nevirapine.

9 fter receipt of a single, peripartum dose of nevirapine.

10 utant associated with clinical resistance to nevirapine.

11 oncentrations after a single 2-mg/kg dose of nevirapine.

12 d against the RT, such as L-697639, TIBO and nevirapine.

13 =48 weeks of treatment with extended-release nevirapine.

14 efavirenz and 2.01 (95% CI, 1.36-2.98) with nevirapine.

15 nant women following single-dose intrapartum nevirapine.

16 .61); lopinavir/ritonavir, 1.23 (0.58-2.59); nevirapine, 1.53 (1.11-2.10); and abacavir, 2.03 (1.26-3

17 49); saquinavir/ritonavir, 0.64 (0.23-1.80); nevirapine, 1.65 (0.90-3.02); and abacavir, 1.82 (0.73-4

18 women without prior exposure to single-dose nevirapine, 34 of 249 in the nevirapine group (14%) and

19 retroviral (4%, 3-6; p=0.0273) or the infant-nevirapine (4%, 2-5; p=0.0027) groups.

20 ive molecules, such as diflufenican (44) and nevirapine (45).

21 ant factors (breast-feeding duration, infant nevirapine administration, gestational age, and birth we

22 s are nearly as active as the antiviral drug nevirapine against a variety of clinical isolates in hum

23 The IC50 value for inhibition by nevirapine against wild-type (WT) RT in our removal assa

24 treatment, 112 had received a single dose of nevirapine and 106 had received placebo.

25 ine began the study treatments (121 received nevirapine and 120 received ritonavir-boosted lopinavir)

26 Infants received single-dose nevirapine and 4 weeks of zidovudine.

27 A (short course zidovudine with single-dose nevirapine and an ARV "tail") and B (combination ART dur

28 utations can confer high-level resistance to nevirapine and delavirdine as well as low level cross-re

29 to the nonnucleoside RT inhibitors (NNRTIs) nevirapine and delavirdine.

30 own to predict increased steady-state plasma nevirapine and efavirenz exposure.

31 g the activity of this inhibitor relative to nevirapine and efavirenz in cell culture.

32 trating that the clinically approved NNRTIs, nevirapine and efavirenz, inhibit the ATP-mediated remov

33 and the pharmacokinetics of single doses of nevirapine and efavirenz.

34 B6 polymorphisms and the pharmacokinetics of nevirapine and efavirenz.

35 ct the steady-state plasma concentrations of nevirapine and efavirenz.

36 rug therapy, treatment with a single dose of nevirapine and interruption of treatment.

37 ions and exhibit a qualitative dependence on nevirapine and ionic strength (KCl) that is similar to t

38 mutations commonly arise in the presence of nevirapine and result in resistance to the drug.

39 to wild-type RT are observed in complexes of nevirapine and the second-generation NNRTI UC-781 with R

40 Extended prophylaxis with nevirapine or with nevirapine and zidovudine for the first 14 weeks of life

41 Extended prophylaxis with nevirapine or with nevirapine and zidovudine significantly reduces postnata

42 to age 14 weeks; or the control regimen plus nevirapine and zidovudine to age 14 weeks.

43 ld increased cross-resistance to etravirine, nevirapine, and efavirenz compared with wild type HIV-1

44 otyping and drug concentrations (lamivudine, nevirapine, and efavirenz) were measured on stored sampl

45 o cyclosporine, has increased sensitivity to nevirapine, and is impaired in macrophage infection prio

46 retroviral (ARV) drugs, including efavirenz, nevirapine, and lamivudine, with nucleoside resistance i

47 children who received stavudine, lamivudine, nevirapine, and nelfinavir had plasma HIV-1 RNA levels o

48 py and treatment with stavudine, lamivudine, nevirapine, and nelfinavir were associated with improved

49 ine in maternal-antiretroviral, 13 in infant-nevirapine, and six in control groups).

50 onnucleoside reverse-transcriptase inhibitor nevirapine, and the antibiotic TMP-SMX were assessed for

51 l status, NRTIs used, receipt of single-dose nevirapine, and treatment for tuberculosis.

52 milarly susceptible to the NNRTIs efavirenz, nevirapine, and UC781.

53 HIV-1 inhibitory concentrations of nevirapine are achieved in breast-feeding infants of mot

54 nscriptase inhibitors (NNRTIs) efavirenz and nevirapine are commonly used in first-line antiretrovira

55 z: ART-naive GMR, 0.43; 90% CI, .42, .44 and nevirapine: ART-naive GMR, 1.14; 90% CI, 1.14, 1.16).

56 z: ART-naive GMR, 0.53; 90% CI, .50, .55 and nevirapine: ART-naive GMR, 1.35; 90% CI, 1.29, 1.43).

57 Cox regression models with nevirapine as a time-varying covariate, stratified by tr

58 Botswana, the use of efavirenz compared with nevirapine as initial antiretroviral treatment was assoc

59 nt of the women who had received intrapartum nevirapine, as compared with 68 percent of the women who

60 who either had or had not taken single-dose nevirapine at least 6 months before enrollment were rand

61 cal Trials Group study A5207, women received nevirapine at onset of labor and were randomly assigned

62 ya, antiretroviral therapy (ART) use, mostly nevirapine based, was associated with lower cure rates o

63 We assessed the effect of efavirenz- or nevirapine-based antiretroviral therapy (ART) coadminist

64 eptive methods and either efavirenz-based or nevirapine-based antiretroviral therapy (ART) regimens.

65 ve cohort study included patients initiating nevirapine-based antiretroviral therapy (ART) with eithe

66 Nevirapine-based antiretroviral therapy is the predomina

67 r rates of virologic failure with subsequent nevirapine-based antiretroviral therapy than did women w

68 However, this applied only when nevirapine-based antiretroviral therapy was initiated wi

69 We studied the response to nevirapine-based antiretroviral treatment among women an

70 (n = 17), efavirenz-based ART (n = 20), and nevirapine-based ART (n = 20).

71 viremia after interruption of efavirenz- or nevirapine-based ART affects outcomes once these drugs a

72 In contrast, nevirapine-based ART did not adversely affect levonorges

73 PV/r-based ART compared with children taking nevirapine-based ART following AL treatment (15.3% vs 35

74 , children <12 months of age were started on nevirapine-based ART if they were eligible, and randomiz

75 contraceptive method and efavirenz-based or nevirapine-based ART regimen.

76 1 per 100 person-years (95% CI 0.72-1.5) for nevirapine-based ART users and 3.3 per 100 person-years

77 .5 per 100 person-years (95% CI 3.7-5.2) for nevirapine-based ART users and 5.4 per 100 person-years

78 f contraceptive failure than did those using nevirapine-based ART, these women still had lower contra

79 hildren taking LPV/r-based ART compared with nevirapine-based ART.

80 /mL (hazard ratio, 1.39 [CI, 1.14 to 1.70]), nevirapine-based regimen (hazard ratio, 1.43 [CI, 1.16 t

81 Switching children once suppressed to a nevirapine-based regimen might be a valuable treatment o

82 s (2.1 vs 11.7 mg/dL, P < .001); patients on nevirapine-based regimens had a higher increase in HDL c

83 of switching nevirapine-exposed children to nevirapine-based treatment after effective suppression o

84 to compare long-term viral suppression with nevirapine-based versus protease-inhibitor-based (ritona

85 nodeficiency virus-infected infants starting nevirapine-based vs lopinavir/ritonavir-based antiretrov

86 41 women who had been exposed to single-dose nevirapine began the study treatments (121 received nevi

87 ith prior exposure to peripartum single-dose nevirapine (but not in those without prior exposure), ri

88 A single dose of nevirapine can establish antiretroviral resistance withi

89 1, only 1 of whom had a history of receiving nevirapine chemoprophylaxis.

90 tributing to the greater loss of binding for nevirapine compared to UC-781 as, in the former case, a

91 Structure of an RT-DNA-nevirapine complex revealed how NNRTI binding forbids RT

92 mothers who are subsequently treated with a nevirapine-containing regimen is unknown.

93 er six months of postpartum treatment with a nevirapine-containing regimen.

94 RT in the presence and absence of the NNRTI nevirapine (cumulative total simulation time, 360 ns).

95 ociated with failure of stavudine-lamivudine-nevirapine (d4T/3TC/NVP; P < .01), and K103N, V106M, and

96 Intrapartum single-dose nevirapine decreases mother-to-child transmission of hum

97 ent with the reverse transcriptase inhibitor nevirapine delayed uncoating in both assays.

98 Maternal receipt of nevirapine did not predict early MTCT in the BF group (P

99 three HIV drugs, (Indinavir, Zidovudine, and Nevirapine), discovered unique interaction features betw

100 clinically relevant treatment levels, while nevirapine does not.

101 A single dose of nevirapine during labor reduces perinatal transmission o

102 , zidovudine for 6 weeks plus three doses of nevirapine during the first 8 days of life (two-drug gro

103 enzymes that are resistant to inhibition by nevirapine, efavirenz, and delaviridine.

104 ed stavudine/zidovudine plus lamivudine plus nevirapine/efavirenz.

105 Among Indians, slower nevirapine elimination was associated with CYP2B6 516G -

106 ir/ritonavir were associated with more rapid nevirapine elimination.

107 present the long-term outcomes of switching nevirapine-exposed children to nevirapine-based treatmen

108 pe) and 155 age-, sex- and ethnicity-matched nevirapine-exposed controls.

109 decrease as the interval between single-dose nevirapine exposure and the start of antiretroviral ther

110 plus daily extended prophylaxis either with nevirapine (extended nevirapine) or with nevirapine plus

111 Four daily regimens were compared: nevirapine for 6 weeks, 14 weeks, or 28 weeks, or nevira

112 research evaluating the use of efavirenz and nevirapine for pediatric patients.

113 children with prior exposure to single-dose nevirapine for perinatal prevention of HIV transmission,

114 Women received zidovudine and single dose nevirapine for PMTCT and were followed until 12 months p

115 han 24 months who were previously exposed to nevirapine for prevention of mother-to-child transmissio

116 efficacy of efavirenz in children exposed to nevirapine for prevention of mother-to-child transmissio

117 Among HIV-infected children exposed to nevirapine for prevention of mother-to-child transmissio

118 rolling 300 HIV-infected children exposed to nevirapine for prevention of mother-to-child transmissio

119 A single intrapartum dose of nevirapine for the prevention of mother-to-child transmi

120 RT and its interaction with the bound NNRTI nevirapine, for both wild-type and mutant (V106A, Y181C,

121 irus (HIV) in resource-limited settings, but nevirapine frequently selects for resistant virus in mot

122 to single-dose nevirapine, 34 of 249 in the nevirapine group (14%) and 36 of 251 in the ritonavir-bo

123 group, as compared with 5.2% in the extended-nevirapine group (P<0.001) and 6.4% in the extended-dual

124 efined toxicity end point was shorter in the nevirapine group (P=0.04), as was the time to death (P=0

125 nificantly between the placebo group and the nevirapine group among 158 women starting antiretroviral

126 ed without prior virologic failure (4 in the nevirapine group and 1 in the ritonavir-boosted lopinavi

127 Virologic failure occurred in 37 (28 in the nevirapine group and 9 in the ritonavir-boosted lopinavi

128 women in the placebo group and 41.7% in the nevirapine group had virologic failure (P<0.001).

129 Significantly more women in the nevirapine group reached the primary end point than in t

130 ry end point was significantly higher in the nevirapine group than in the ritonavir-boosted lopinavir

131 More children in the nevirapine group than in the ritonavir-boosted lopinavir

132 tment (15 in the placebo group and 15 in the nevirapine group).

133 ernal-antiretroviral group, 25 in the infant-nevirapine group, and 38 in the control group became HIV

134 rnal-antiretroviral group, 680 in the infant-nevirapine group, and 542 in the control group.

135 maternal-antiretroviral group, two in infant-nevirapine group, six in control group).

136 d 710 pg/mL in the ART-naive, efavirenz, and nevirapine groups, respectively (efavirenz: ART-naive GM

137 d 664 pg/mL in the ART-naive, efavirenz, and nevirapine groups, respectively (efavirenz: ART-naive GM

138 No pregnancies occurred in the ART-naive or nevirapine groups.

139 and 34/39 (87.2%) patients showed measurable nevirapine (>0.25 ng/ml) or efavirenz (>5 ng/ml) concent

140 % CI, 22.0%-31.1%) initiating treatment with nevirapine had virological failure.

141 resource-limited countries, a single dose of nevirapine has been widely prescribed to pregnant women

142 tified 117 HIV-infected Malawian adults with nevirapine hypersensitivity (15 drug-induced liver injur

143 tigen (HLA) markers that are associated with nevirapine hypersensitivity.

144 ositive adults starting stavudine/lamivudine/nevirapine in Malawi, using Sanger, deep, clonal, and si

145 Val108 does not have direct contact with nevirapine in wild-type RT and in the RT(Val108Ile) comp

146 ceptibility was reduced in 93% for efavirenz/nevirapine, in 81% for lamivudine/emtricitabine, in 59%

147 quantify two different drugs, lapatinib and nevirapine, in dosed tissues from nonclinical species an

148 e contributed to the suboptimal results with nevirapine include elevated viral load at baseline, sele

149 Nevirapine increased the risk of TAMs, K65R, and Q151M.

150 s within the HLA-DQB1 loci protected against nevirapine-induced hypersensitivity phenotypes.

151 JS/TEN, 20 hypersensitivity syndrome, and 46 nevirapine-induced rash plus 3 with both DILI and SJS ph

152 ed HLA-C*04:01 carriage as a risk factor for nevirapine-induced SJS/TEN in a Malawian HIV cohort.

153 (median, 9534 ng/mL at a median of 4 h after nevirapine ingestion).

154 ential for beneficial and adverse effects of nevirapine ingestion.

155 nn surface accessibility (MM-PBSA) show that nevirapine interacts stronger with wild-type RT than wit

156 However, nevirapine is associated with a 6%-10% risk of developin

157 Nevirapine is metabolized by cytochrome P450 (CYP) 2B6 a

158 Single-dose nevirapine is the cornerstone of the regimen for prevent

159 onnucleoside reverse transcriptase inhibitor nevirapine is the cornerstone of treatment for human imm

160 n who have had prior exposure to single-dose nevirapine is unknown.

161 Since nevirapine is used for both treatment and perinatal prev

162 r-emtricitabine or tenofovir-lamivudine plus nevirapine is used in many resource-constrained settings

163 We measured concentrations of nevirapine, lamivudine, and zidovudine in serum and whol

164 Median breast-milk concentrations of nevirapine, lamivudine, and zidovudine were 0.67, 3.34,

165 ads of women in Botswana who received HAART (nevirapine, lamivudine, and zidovudine) and women who di

166 inhibitory concentration (IC50), and week 5 nevirapine level below the quantification limit.

167 Plasma nevirapine level was quantified on postpartum day 1 and

168 n plasma drug exposure following single-dose nevirapine may be greater for CYP2B6 983T --> C than for

169 nt HIV-1 after administration of single-dose nevirapine may not differ substantially according to CYP

170 All mothers and infants received one dose of nevirapine (mother 200 mg; infant 2 mg/kg) and 7 days of

171 triple antiretroviral (n=849); daily infant nevirapine (n=852); or control (n=668).

172 after receiving placebo or a single dose of nevirapine, no women in the placebo group and 41.7% in t

173 1 of 2472 [36.4%]) compared with TDF-FTC and nevirapine (NVP) (317 of 760 [41.7%]; ARR, 1.15; 95% CI,

174 DF-containing regimens: TDF/lamivudine (3TC)/nevirapine (NVP) (n = 3), TDF/ emtricitabine (FTC)/NVP (

175 duce RNase H cleavage, enhance resistance to nevirapine (NVP) and delavirdine (DLV), but not to efavi

176 ials compared lopinavir/ritonavir (LPV/r) to nevirapine (NVP) for antiretroviral therapy and showed a

177 d in some women who receive single-dose (SD) nevirapine (NVP) for prevention of HIV-1 mother-infant t

178 immunodeficiency virus (HIV) and exposed to nevirapine (NVP) for prevention of mother-to-child trans

179 eriority of lopinavir/ritonavir (LPV/r) over nevirapine (NVP) in antiretroviral therapy (ART), regard

180 ptase inhibitors (NNRTI) efavirenz (EFV) and nevirapine (NVP) in first-line antiretroviral therapy (A

181 Nevirapine (NVP) is widely used in antiretroviral treatm

182 Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human

183 HIV status without receiving the HIVNET 012 nevirapine (NVP) regimen (a single oral dose of NVP to t

184 Nevirapine (NVP) resistance emerges in up to 70% of wome

185 We analyzed the development of nevirapine (NVP) resistance in human immunodeficiency vi

186 ligation assay (OLA) to probe for low-level nevirapine (NVP) resistance mutations K103N and Y181C in

187 Single-dose (SD) nevirapine (NVP) significantly reduces mother-to-child t

188 structures of RT-RNA/DNA-dATP and RT-RNA/DNA-nevirapine (NVP) ternary complexes at 2.5 and 2.9 A reso

189 The interaction of the NNRTI nevirapine (NVP) with HIV-1 reverse transcriptase (RT) i

190 Nevirapine (NVP), is an HIV-1 antiretroviral with treatm

191 Additionally, we showed that another NNRTI, nevirapine (NVP), stimulated K101E+G190S virus replicati

192 Acquisition of nevirapine (NVP)-resistant human immunodeficiency virus

193 Low-frequency nevirapine (NVP)-resistant variants have been associated

194 er-to-child transmission of HIV-1 can select nevirapine (NVP)-resistant variants, but the frequency,

195 hemical mechanism of resistance to the NNRTI nevirapine (NVP).

196 NRTI; Efavirenz, Etravirine, Rilpivirine and Nevirapine) on the integrity of the blood-brain barrier,

197 ren of these women received either 1 dose of nevirapine or 1 dose of nevirapine plus 1 week of daily

198 In a randomized comparison of nevirapine or abacavir with zidovudine plus lamivudine,

199 ce interval [CI] 1.52, 38.30; p = 0.01) with nevirapine or efavirenz concentrations above vs. below t

200 Moreover, it attenuated resistance to nevirapine or efavirenz imparted by NNRTI mutations.

201 side reverse transcriptase inhibitor (NNRTI; nevirapine or efavirenz) in sub-Saharan Africa.

202 ere associated with high-level resistance to nevirapine or efavirenz, whereas only 27% of NRTI SDRMs

203 ation paediatric tablets with lamivudine and nevirapine or efavirenz.

204 mly assigned to a single, peripartum dose of nevirapine or placebo in a trial in Botswana involving t

205 s received zidovudine as well as single-dose nevirapine or placebo.

206 fants were randomized to receive single-dose nevirapine or placebo.

207 ment with zidovudine, lamivudine, and either nevirapine or ritonavir-boosted lopinavir in HIV-infecte

208 y with zidovudine and lamivudine plus either nevirapine or ritonavir-boosted lopinavir in HIV-infecte

209 al therapy with tenofovir-emtricitabine plus nevirapine or tenofovir-emtricitabine plus lopinavir boo

210 Extended prophylaxis with nevirapine or with nevirapine and zidovudine for the fir

211 Extended prophylaxis with nevirapine or with nevirapine and zidovudine significant

212 prophylaxis either with nevirapine (extended nevirapine) or with nevirapine plus zidovudine (extended

213 % of those who had received a single dose of nevirapine (P=0.002).

214 f the women who had not received intrapartum nevirapine (P=0.03).

215 children had HIVDR that was associated with nevirapine perinatal exposure (P < .001).

216 ved either 1 dose of nevirapine or 1 dose of nevirapine plus 1 week of daily doses of zidovudine.

217 signed to one of three regimens: single-dose nevirapine plus 1 week of zidovudine (control regimen) o

218 eceive a either control regimen (single-dose nevirapine plus 1 week of zidovudine); the control regim

219 bic millimeter to zidovudine and single-dose nevirapine plus a 1-to-2-week postpartum "tail" of tenof

220 plus tenofovir-emtricitabine was superior to nevirapine plus tenofovir-emtricitabine for initial anti

221 ith nevirapine (extended nevirapine) or with nevirapine plus zidovudine (extended dual prophylaxis) u

222 apine for 6 weeks, 14 weeks, or 28 weeks, or nevirapine plus zidovudine for 14 weeks.

223 en, 4.8% (95% CI, 3.5%-6.7%) for the 14-week nevirapine plus zidovudine regimen, and 1.8% (95% CI, 1.

224 than 200 cells per cubic millimeter received nevirapine plus zidovudine-lamivudine (the observational

225 re pooled to estimate the efficacy of infant nevirapine prophylaxis to prevent breast-milk HIV-1 tran

226 al triple-antiretroviral prophylaxis, infant-nevirapine prophylaxis, or neither) factorial design.

227 with HIV who have been previously exposed to nevirapine prophylaxis.

228 hat included children exposed to single-dose nevirapine prophylaxis.

229 eased lumefantrine exposure by 2.1-fold; and nevirapine reduced artemether exposure only.

230 Single-dose nevirapine reduces intrapartum human immunodeficiency vi

231 Peripartum administration of single-dose nevirapine reduces mother-to-child transmission of human

232 ount and infant birth weight, indicated that nevirapine reduces the rate of HIV-1 infection by 71% (9

233 and 1.8% (95% CI, 1.0%-3.1%) for the 28-week nevirapine regimen (log-rank test for trend, P < .001).

234 nce interval [CI], 4.3%-7.9%) for the 6-week nevirapine regimen, 3.7% (95% CI, 2.5%-5.4%) for the 14-

235 en, 3.7% (95% CI, 2.5%-5.4%) for the 14-week nevirapine regimen, 4.8% (95% CI, 3.5%-6.7%) for the 14-

236 Nevirapine resistance after exposure to the drug for pre

237 sequencing of baseline plasma samples showed nevirapine resistance in 33 of 239 women tested (14%).

238 OLA detected nevirapine resistance in more specimens than consensus s

239 sent in each blood sample (mean, 162 cells), nevirapine resistance mutations (K103N and G190A) were d

240 irus type 1 (HIV-1) but often leads to viral nevirapine resistance mutations in mothers and infants.

241 The proportion of women whose nevirapine resistance was detected by OLA 10 days after

242 Nevirapine resistance was found in 7/16 (43.5%) HIV-1-po

243 evated viral load at baseline, selection for nevirapine resistance, background regimen of nucleoside

244 deficiency virus type 1 (HIV-1) but promotes nevirapine resistance.

245 These viruses were then analyzed for nevirapine resistance.

246 stant (UCR), efavirenz-resistant (EFVR), and nevirapine-resistant (NVPR) strains in a variety of micr

247 Nevirapine-resistant HIV-1 genotypes (with the mutations

248 the importance of understanding the decay of nevirapine-resistant mutants.

249 potentially lifelong risk of reemergence of nevirapine-resistant virus and highlights the need for s

250 iciency virus type 1 (HIV-1) but selects for nevirapine-resistant virus.

251 oncentration had no effect on removal by the nevirapine-resistant Y181C mutant.

252 Single-dose nevirapine (SD NVP) at birth plus NVP prophylaxis for th

253 trial in Uganda, 6-8 weeks after single-dose nevirapine (SD-NVP), NVP resistance mutations were detec

254 y after they receive intrapartum single-dose nevirapine (SD-NVP).

255 dren after the administration of single-dose nevirapine (SD-NVP).

256 herapy (ART) in women exposed to single-dose nevirapine (sdNVP) >/= 6 mo earlier, the primary endpoin

257 Single-dose nevirapine (sdNVP) for prevention of mother-to-child tra

258 Single-dose nevirapine (sdNVP) given to prevent mother-to-child-tran

259 A single dose of nevirapine (sdNVP) to prevent mother-to-child transmissi

260 TCT regimens were evaluated: (1) single-dose nevirapine (sdNVP), (2) WHO 2010 guidelines' "Option A"

261 Single-dose nevirapine (sdNVP)-based regimens reduce mother-to-child

262 rdant care for 4 PMTCT regimens: single-dose nevirapine (sdNVP); WHO-recommended Option A, WHO-recomm

263 fected cohorts of the Six Week Extended-Dose Nevirapine (SWEN) Study, a study comparing extended nevi

264 95% confidence interval [CI], 1.11-2.84) and nevirapine/tenofovir (27% vs 11%; AOR, 2.09; 95% CI, 1.2

265 or emtricitabine with efavirenz/tenofovir or nevirapine/tenofovir.

266 re infants who had received a single dose of nevirapine than in infants who had received placebo (P<0

267 t-line regimen of stavudine, lamivudine, and nevirapine the benefits of viral load or CD4 cell count

268 from treatment of HIV-infected patients with nevirapine, the first-in-class drug still widely used, e

269 of whether there has been prior exposure to nevirapine, the performance of nevirapine versus ritonav

270 nt of the women who had received intrapartum nevirapine; the most frequent mutations were K103N, G190

271 "Option A" (zidovudine in pregnancy, infant nevirapine throughout breastfeeding for women without ad

272 eek of zidovudine); the control regimen plus nevirapine to age 14 weeks; or the control regimen plus

273 fter administration of a 200-mg oral dose of nevirapine to nonpregnant, HIV-negative African American

274 Women who received a single dose of nevirapine to prevent perinatal transmission of HIV-1 ha

275 as compared with zidovudine and single-dose nevirapine to prevent transmission of the human immunode

276 t-line regimen of stavudine, lamivudine, and nevirapine to second-line antiretroviral treatment.

277 Studies evaluating daily nevirapine to the breastfeeding infant suggest protectio

278 ical trials indicate daily administration of nevirapine to the infant can prevent breast-milk HIV-1 t

279 aring extended nevirapine versus single-dose nevirapine, to reduce MTCT of HIV among breast-fed infan

280 Among the nevirapine-treated children with virologic failure for w

281 d mothers) within the Six-Week Extended-Dose Nevirapine trial.

282 ty variant copy numbers, non-white race, and nevirapine use were associated with a higher risk of NNR

283 r exposure to nevirapine, the performance of nevirapine versus ritonavir-boosted lopinavir in young c

284 ine (SWEN) Study, a study comparing extended nevirapine versus single-dose nevirapine, to reduce MTCT

285 Among the women who had received intrapartum nevirapine, viral suppression was achieved at six months

286 and an extended release version of the NNRTI nevirapine, (Viramune XR((R))) were recent additions to

287 clinical trial with peripartum (single-dose nevirapine vs placebo) and postpartum infant feeding (fo

288 e also assessed the influence of concomitant nevirapine vs. efavirenz, therapy duration, and HIV-1 su

289 Regardless of concomitant nevirapine vs. efavirenz, therapy duration, or subtype,

290 The median infant serum concentration of nevirapine was 971 ng/mL, at least 40 times the 50% inhi

291 ivudine or emtricitabine in combination with nevirapine was a strong predictor of virologic failure i

292 Baseline resistance to nevirapine was detected in 18 of 148 children (12%) and

293 Susceptibility to the NNRTIs efavirenz and nevirapine was inversely proportional to the level of en

294 Rather, a approximately 83-fold increase in nevirapine was required to decrease the rate of removal

295 Maternal serum concentrations of nevirapine were high (median, 9534 ng/mL at a median of

296 Women who received intrapartum nevirapine were less likely to have virologic suppressio

297 children (5.2%; 95% CI, 3.2%-7.9%) receiving nevirapine who never achieved virological suppression.

298 e inhibitors were associated with higher and nevirapine with lower IL-6 levels.

299 *58:01, and both amoxicillin-clavulanate and nevirapine with multiple class I and II alleles.

300 (zidovudine until delivery with single-dose nevirapine without postpartum prophylaxis).